vs

Side-by-side financial comparison of Boxlight Corp (BOXL) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Boxlight Corp is the larger business by last-quarter revenue ($29.3M vs $19.6M, roughly 1.5× STANDARD BIOTOOLS INC.). Boxlight Corp runs the higher net margin — -21.1% vs -177.4%, a 156.3% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -19.2%). Over the past eight quarters, STANDARD BIOTOOLS INC.'s revenue compounded faster (-12.2% CAGR vs -23.1%).

Boxlight Corp is a global provider of interactive technology solutions, including interactive flat panel displays, projectors, collaborative software, and classroom technology accessories. It primarily serves K-12 and higher education institutions, as well as corporate and government customers across North America, Europe, and Asia Pacific, focusing on enhancing learning and work collaboration efficiency.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

BOXL vs LAB — Head-to-Head

Bigger by revenue
BOXL
BOXL
1.5× larger
BOXL
$29.3M
$19.6M
LAB
Growing faster (revenue YoY)
LAB
LAB
+7.7% gap
LAB
-11.5%
-19.2%
BOXL
Higher net margin
BOXL
BOXL
156.3% more per $
BOXL
-21.1%
-177.4%
LAB
Faster 2-yr revenue CAGR
LAB
LAB
Annualised
LAB
-12.2%
-23.1%
BOXL

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
BOXL
BOXL
LAB
LAB
Revenue
$29.3M
$19.6M
Net Profit
$-6.2M
$-34.7M
Gross Margin
29.1%
48.5%
Operating Margin
-13.4%
-168.5%
Net Margin
-21.1%
-177.4%
Revenue YoY
-19.2%
-11.5%
Net Profit YoY
-102.0%
-28.8%
EPS (diluted)
$-1.88
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BOXL
BOXL
LAB
LAB
Q3 25
$29.3M
$19.6M
Q2 25
$30.9M
$21.8M
Q1 25
$40.8M
Q4 24
$24.0M
Q3 24
$36.3M
$22.1M
Q2 24
$38.5M
$22.5M
Q1 24
$37.1M
$45.5M
Q4 23
$38.8M
$28.2M
Net Profit
BOXL
BOXL
LAB
LAB
Q3 25
$-6.2M
$-34.7M
Q2 25
$-4.7M
$-33.5M
Q1 25
$-26.0M
Q4 24
$-16.7M
Q3 24
$-3.1M
$-26.9M
Q2 24
$-1.5M
$-45.7M
Q1 24
$-7.1M
$-32.2M
Q4 23
$-17.7M
$-19.8M
Gross Margin
BOXL
BOXL
LAB
LAB
Q3 25
29.1%
48.5%
Q2 25
35.0%
48.8%
Q1 25
48.4%
Q4 24
30.6%
Q3 24
33.8%
54.9%
Q2 24
37.7%
46.1%
Q1 24
34.5%
53.1%
Q4 23
31.7%
47.6%
Operating Margin
BOXL
BOXL
LAB
LAB
Q3 25
-13.4%
-168.5%
Q2 25
-12.7%
-118.1%
Q1 25
-80.8%
Q4 24
-67.6%
Q3 24
-2.4%
-120.9%
Q2 24
3.2%
-134.5%
Q1 24
-9.7%
-132.2%
Q4 23
-42.8%
-75.9%
Net Margin
BOXL
BOXL
LAB
LAB
Q3 25
-21.1%
-177.4%
Q2 25
-15.3%
-153.7%
Q1 25
-63.8%
Q4 24
-69.6%
Q3 24
-8.4%
-122.0%
Q2 24
-3.8%
-203.3%
Q1 24
-19.1%
-70.6%
Q4 23
-45.5%
-70.2%
EPS (diluted)
BOXL
BOXL
LAB
LAB
Q3 25
$-1.88
$-0.09
Q2 25
$-1.53
$-0.09
Q1 25
$-0.07
Q4 24
$-87.29
Q3 24
$-1.72
$-0.07
Q2 24
$-0.92
$-0.12
Q1 24
$-0.76
$-0.27
Q4 23
$-19.01
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BOXL
BOXL
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$11.8M
$129.4M
Total DebtLower is stronger
$36.7M
Stockholders' EquityBook value
$-19.5M
$399.7M
Total Assets
$99.6M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BOXL
BOXL
LAB
LAB
Q3 25
$11.8M
$129.4M
Q2 25
$7.6M
$158.6M
Q1 25
$150.9M
Q4 24
$8.0M
Q3 24
$10.5M
$210.6M
Q2 24
$7.5M
$269.8M
Q1 24
$11.8M
$287.1M
Q4 23
$17.3M
$51.7M
Total Debt
BOXL
BOXL
LAB
LAB
Q3 25
$36.7M
Q2 25
$39.0M
Q1 25
Q4 24
$37.1M
Q3 24
$38.8M
$55.2M
Q2 24
$40.3M
$55.1M
Q1 24
$38.5M
$55.0M
Q4 23
$40.2M
$63.5M
Stockholders' Equity
BOXL
BOXL
LAB
LAB
Q3 25
$-19.5M
$399.7M
Q2 25
$-20.6M
$424.5M
Q1 25
$454.6M
Q4 24
$-12.9M
Q3 24
$6.5M
$489.3M
Q2 24
$7.5M
$510.3M
Q1 24
$9.1M
$577.3M
Q4 23
$16.8M
$-148.1M
Total Assets
BOXL
BOXL
LAB
LAB
Q3 25
$99.6M
$539.6M
Q2 25
$99.2M
$557.0M
Q1 25
$579.6M
Q4 24
$115.3M
Q3 24
$142.9M
$681.5M
Q2 24
$141.3M
$708.7M
Q1 24
$142.4M
$777.7M
Q4 23
$161.8M
$323.1M
Debt / Equity
BOXL
BOXL
LAB
LAB
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
5.93×
0.11×
Q2 24
5.38×
0.11×
Q1 24
4.23×
0.10×
Q4 23
2.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BOXL
BOXL
LAB
LAB
Operating Cash FlowLast quarter
$1.3M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BOXL
BOXL
LAB
LAB
Q3 25
$1.3M
$-22.2M
Q2 25
$-20.7M
Q1 25
$-30.3M
Q4 24
$1.6M
Q3 24
$5.2M
$-27.9M
Q2 24
$-5.4M
$-39.0M
Q1 24
$-1.9M
$-62.5M
Q4 23
$3.3M
$-14.1M
Free Cash Flow
BOXL
BOXL
LAB
LAB
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
FCF Margin
BOXL
BOXL
LAB
LAB
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Capex Intensity
BOXL
BOXL
LAB
LAB
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Q4 23
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BOXL
BOXL

Products$27.4M93%
Services$2.0M7%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons